Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus
- 1 May 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (5), 930-934
- https://doi.org/10.1161/01.atv.0000124890.40436.77
Abstract
Objectives— Thiazolidinediones, such as rosiglitazone, have been shown to retard atherosclerosis disease progression in diabetic subjects. These agents may have anti-atherosclerotic effects through direct inhibition of inflammatory processes in the vessel wall, and so their benefit may extend to patients with atherosclerotic disease, even in the absence of diabetes. In this study, we assessed the effect of rosiglitazone on common carotid intima-media thickness (IMT) progression in nondiabetic coronary artery disease (CAD) patients. Methods and Results— Consecutive subjects (n=92) with clinically stable, angiographically documented CAD and without diabetes mellitus were randomized in a double-blind manner to receive placebo or rosiglitazone for 48 weeks. They received single-dose placebo and rosiglitazone 4 mg daily for the initial 8 weeks, and the doses were doubled for the remainder of the study. Common carotid IMT together with fasting glucose, insulin, and lipid profile were measured at baseline and repeated after 24 and 48 weeks. Rosiglitazone-treated patients showed reduced IMT progression compared with the placebo group, −0.012 mm/48 weeks versus 0.031 mm/48 weeks ( P =0.03). Rosiglitazone treatment significantly reduced insulin resistance, estimated by homeostasis model of insulin resistance index, compared with placebo ( P =0.01). Conclusions— Rosiglitazone reduces common carotid IMT progression in nondiabetic CAD patients, and insulin-sensitization may be one contributory mechanism.Keywords
This publication has 18 references indexed in Scilit:
- The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patientsJournal of the American College of Cardiology, 2003
- Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- RAPID COMMUNICATION: Inhibitory Effect of Pioglitazone on Carotid Arterial Wall Thickness in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2001
- Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptorProceedings of the National Academy of Sciences of the United States of America, 2001
- Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound studyAtherosclerosis, 2000
- Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient miceJCI Insight, 2000
- Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiographyAtherosclerosis, 2000
- Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjectsInternational Journal of Obesity, 1999
- Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 1998
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985